Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

33.3%

1 terminated out of 3 trials

Success Rate

0.0%

-86.5% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

3Total
P 1 (2)
P 2 (1)

Trial Status

Withdrawn1
Active Not Recruiting1
Terminated1

Clinical Trials (3)

Showing 3 of 3 trials
NCT03435952Phase 1Active Not Recruiting

Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT

NCT03258008Phase 2TerminatedPrimary

Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer

NCT02915172Phase 1Withdrawn

Lenvatinib and Capecitabine in Patients With Advanced Malignancies

Showing all 3 trials

Research Network

Activity Timeline